HCRI Biorepository Director; Research Assistant Professor of Chemistry & Biochemistry at the University of Notre Dame
University of Notre Dame
Next-generation sequencing and cancer biomarkers
Zonggao Shi earned his doctorate in cancer pathology at Fudan University (Shanghai, China) in 2001 and is Director of the Biosample Repository at HCRI. The primary function of the Repository is the procurement and management of normal and neoplastic tissues and cell lines from humans and experimental animals. In addition to cryopreservation and common storage and management, the repository is fully equipped and staffed for routine histopathology, tissue microarray (TMA) construction (Veridiam tissue arrayer), laser capture microdissection (Arcturus XT system) for accurate sampling, and digital pathology (Aperio ScanScope CS). This shared core facility welcomes all types of service requests and collaborations.
Beyond his role in biorepository service, Dr. Shi continues his research pursuits in cancer molecular pathology, with high-throughput sequencing technology as a leading tool in addition to morphology-based methods. His long-term efforts are focused on better understanding of the molecular mechanisms of cancer metastasis. His current studies are exploring the use of high throughput sequencing technologies, especially targeted sequencing panels and bioinformatics in cancer biomarker discovery and in mechanistic studies on cancer cell adhesion, invasion and cancer metastasis. Dr. Shi is also interested in developing more efficient cellular and animal models to enhance the study of cancer metastasis.
1. Shi Z, Li C, Tarwater L, Li J, Li Y, Kaliney W, Chandrashekar DS, Stack MS. RNA-seq reveals the overexpression of IGSF9 in endometrial cancer. J Oncol. 2018 Feb; 2018, 2439527:1-13. doi:10.1155/2018/2439527
2. Sutton BC, Birse RT, Maggert K, Ray T, Hobbs J, Ezenekwe A, Kazmierczak J, Mosko M, Kish J, Bullock A, Shi Z, Stack MS, Irwin D. Assessment of common somatic mutations of EGFR, KRAS, BRAF, NRAS in pulmonary non-small cell carcinoma using iPLEX® HS, a new highly sensitive assay for the MassARRAY® System. PLoS One. 2017 Sep 19;12(9):e0183715. doi: 10.1371/journal.pone.0183715.
3. Sawe RT, Kerper M, Badve S, Li J, Sandoval-Cooper M, Xie J, Shi Z, Patel K, Chumba D, Ofulla A, Prosperi J, Taylor K, Stack MS, Mining S, Littlepage LE. Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration. BMC Cancer. 2016 Mar 10;16:204. doi: 10.1186/s12885-016-2204-6.
4. Shi Z, Johnson JJ, Jiang R, Liu Y, Stack MS. Decrease of miR-146a is associated with the aggressiveness of human oral squamous cell carcinoma. Arch Oral Biol. 2015 Sep;60(9):1416-27. doi: 10.1016/j.archoralbio.2015.06.007.
5. Miller DL, Davis JW, Taylor KH, Johnson J, Shi Z, Williams R, Atasoy U, Lewis JS Jr, Stack MS. Identification of a human papillomavirus-associated oncogenic miRNA panel in human oropharyngeal squamous cell carcinoma validated by bioinformatics analysis of the Cancer Genome Atlas. Am J Pathol. 2015 Mar;185(3):679-92. doi: 10.1016/j.ajpath.2014.11.018.